IPEC e-newsletter - Excipients Insight March 2018 - 28-03-18

 

Inside this issue

     

MEPs back Amsterdam for EMA

The law enacting the European Medicines Agency’s relocation from London to Amsterdam, due to Brexit, was approved by MEPs earlier this month.

The MEPs did however press the European Commission and the Dutch authorities to deliver the new facilities on time, so as to ensure a smooth transition for the agency and let it move to its temporary location no later than 1 January 2019 and to its new permanent headquarters no later than 16 November 2019.

Lead MEP Giovanni La Via (EPP, IT) said “We are concerned about the risk of delay in the construction of the new Vivaldi building in Amsterdam, as this could cause a deterioration of the agency’s workflow, which is precisely what we want to avoid.”

Earlier this year Giuseppe Sala, the mayor of Milan which lost out to Amsterdam at the final hurdle in the EMA relocation bidding process, said that Italy would lodge an appeal against the decision on the grounds Amsterdam did not have an appropriate temporary building ready to house it and concerns that there may be delays to the construction of the permanent facility.

La Via, who was part of a delegation from the EP to Amsterdam last month to look at the temporary accommodation, said: “We added conditions to the legislative text, in order to highlight the delivery deadlines to be respected and to set an obligation to report every three months on the state of play of the building’s adjustments and construction, by the Commission and Dutch authorities.”

The resolution was passed by 507 votes to 112, with 37 abstentions. MEPs will now start informal three-way (‘trilogue’) negotiations with the Council Presidency and Commission in order to strike a first-reading agreement on the new EMA seat.

“Member states should not expect the European Parliament just to rubber-stamp their decisions,” said La Via. “We regret that its role of co-legislator was not respected, and that is why we want this decision to be taken to a trilogue, under the co-decision procedure”.

 

 

 

Copyright © 2005 - 2018 IPEC Europe - International Pharmaceutical Excipients Council